Pfizer Begins Phase 3 Trial for New Pneumococcal Vaccine in Infants
Pfizer has initiated a late-stage clinical trial for its pneumococcal vaccine, PF-07872412 (25vPnC), targeting infants. The vaccine outperformed Prevnar 20 in earlier trials and is now being tested at the Phase 3 stage.
Tickers: $PFE
Topics: immunology pharmaceuticals Phase 3 trials